Edit Varkondi
Overview
Explore the profile of Edit Varkondi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vodicska B, Deri J, Tihanyi D, Varkondi E, Kispeter E, Doczi R, et al.
World J Pediatr
. 2023 May;
PMID: 37247168
No abstract available.
2.
Vodicska B, Deri J, Tihanyi D, Varkondi E, Kispeter E, Doczi R, et al.
World J Pediatr
. 2023 Mar;
19(10):992-1008.
PMID: 36914906
Background: The utility of routine extensive molecular profiling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown significance or low evidence...
3.
Remenar E, Doczi R, Dirner A, Sipos A, Perjesi A, Tihanyi D, et al.
JCO Precis Oncol
. 2022 Jan;
6:e2100344.
PMID: 35005996
No abstract available.
4.
Szkukalek J, Doczi R, Dirner A, Boldizsar A, Varga A, Deri J, et al.
Diagnostics (Basel)
. 2021 Oct;
11(10).
PMID: 34679548
Background: We present the case of a 50-year-old female whose metastatic pancreatic neuroendocrine tumor (pNET) diagnosis was delayed by the COVID-19 pandemic. The patient was in critical condition at the...
5.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, et al.
NPJ Precis Oncol
. 2021 Jun;
5(1):59.
PMID: 34162980
Precision oncology is currently based on pairing molecularly targeted agents (MTA) to predefined single driver genes or biomarkers. Each tumor harbors a combination of a large number of potential genetic...
6.
Urban L, Doczi R, Vodicska B, Tihanyi D, Horvath M, Kormos D, et al.
Clin Lung Cancer
. 2020 Oct;
22(1):e112-e115.
PMID: 33082101
No abstract available.
7.
Urban L, Doczi R, Vodicska B, Kormos D, Toth L, Takacs I, et al.
J Pers Med
. 2020 Sep;
10(3).
PMID: 32872120
Background: The anaplastic lymphoma kinase () gene fusion rearrangement is a potent oncogene, accounting for 2-7% of lung adenocarcinomas, with higher incidence (17-20%) in non-smokers. -positive tumors are sensitive to...
8.
Brauswetter D, Gurbi B, Varga A, Varkondi E, Schwab R, Banhegyi G, et al.
PLoS One
. 2017 Sep;
12(9):e0185687.
PMID: 28957417
Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream...
9.
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, et al.
Lung Cancer
. 2013 Nov;
83(1):109-11.
PMID: 24192513
The initial radiotherapy of a 73 years old Caucasian male patient with advanced squamous cell lung carcinoma was terminated due to severe pericarditis. Subsequently, the tumor sample was analyzed for...
10.
Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, Banhegyi P, Szabo G, et al.
Curr Opin Mol Ther
. 2009 May;
11(3):308-21.
PMID: 19479664
Abnormally elevated EGFR kinase activity can lead to various pathological states, including proliferative diseases such as cancer. The development of selective protein kinase inhibitors has become an important area of...